





**Food and Agriculture** Nations

Intergovernmental Organization of the United Oceanographic Commission of UNESCO (IOC)

**World Health Organization** 

# Report of the Joint FAO/IOC/WHO ad hoc Expert **Consultation on Biotoxins in Bivalve Molluscs**

Oslo, Norway, 26-30 September 2004

SHORT SUMMARY

**IOC/INF-1215** 

**UNESCO 2005** 

(SC-2005/WS/24)

# Short Summary of the Joint FAO/IOC/WHO *ad hoc* Expert Consultation on Biotoxins in Bivalve Molluscs1

Full report at <a href="http://ftp.fao.org/es/esn/food/biotoxin\_report\_en.pdf">http://ftp.fao.org/es/esn/food/biotoxin\_report\_en.pdf</a>

#### The IOC Intergovernmental Panel on Harmful Algal Blooms (IPHAB) established through Resolution IPHAB-VI.2 a Task Team to address incompatibilities in national and regional biotoxin regulations. Upon invitation by WHO, the Task Team merged into a Joint FAO/IOC/WHO *ad hoc* Expert Consultation on Biotoxins in Bivalve Molluscs.

A Joint FAO/IOC/WHO Expert Workshop on Biotoxins in Molluscan Bivalves was held in Dublin, Ireland, 22–24 March 2003, to draft a technical report to address specific questions posed by the Codex Committee on Fish and Fisheries products (CCFFP) (see the report of the 26<sup>th</sup> session, ALINORM 04/27/18, paragraph 130 at:

ftp://ftp.fao.org/docrep/fao/meeting/008/j1682e.pdf).

The Joint FAO/IOC/WHO Expert Consultation subsequently met in Oslo, 26–30 Norway, Sept. 2004 to review the technical reports prepared and to provide scientific responses to the CCFFP questions:

- Provide scientific advice to the CCFFP to enable the establishment of maximum levels in shellfish for shellfish toxins;
- Provide guidance on methods of analysis for each toxin group;
- Provide guidance on monitoring of biotoxin-forming phytoplankton and bivalve molluscs (including sampling methodology);
- Provide information on geographical distribution of biotoxin-forming marine phytoplankton.

# **Establishment of Guidance Levels/ Maximum Levels:**

The Expert Consultation categorized the biotoxins into 8 distinct groups based on chemical structure. Then risk assessments were carried out in a stepwise fashion, including hazard identification, hazard characterization, exposure assessment and risk characterization. Based on the available information, the Expert Consultation derived the following provisional acute reference doses for four toxin groups: azaspiracid (0.04  $\mu$ g/kg bw), okadaic acid (0.33  $\mu$ g/kg bw), saxitoxin (0.7  $\mu$ g/kg bw), and domoic acid (100  $\mu$ g/kg bw). A provisional acute reference dose of 50  $\mu$ g/kg bw was suggested for the yessotoxin group. The database for the cyclic imines, brevetoxins and pectenotoxins was insufficient to establish provisional acute reference doses for these toxin groups. Table 1 shows the derived guidance levels comparing results based on the consumption of 100g, 250g or 380g shellfish meat by adults.

# **Methods of Analysis**

Test methods for the 8 toxin groups were reviewed and recommendations for Codex purposes have been made. Most methods currently available do not strictly meet criteria for

<sup>1.</sup> also translated into French

Codex Type II or III methods. However, the recommendations represent the best currently available methods. The Expert Consultation recommended that where toxin groups are complex, the implementation of a marker compound concept and the use of functional assays should be explored. There is an urgent need to develop additional certified analytical standards and reference materials.

# **Specific Toxin Groups**

## Azaspiracid (AZA) group

- Limited data in humans indicate a lowest observable adverse effect level between 23 and 86  $\mu$ g/person for acute gastrointestinal effects. The Expert Consultation established a provisional acute reference dose of 0.04  $\mu$ g/kg bw. Because of insufficient data on the chronic effects of AZA, no tolerable daily intake could be established.
- No analytical methods currently meet Codex criteria for Type II or III methods. It is recommended that a liquid chromatography-mass spectrometry method be validated to fully meet Codex Type II or III criteria. Applicability of the technique is currently limited by the lack of certified analytical standards.

## Brevetoxin group

- Only one episode of acute human illness has been reported for brevetoxins (estimated concentrations were 120-472 µg PbTx-3 equivalents/100g shellfish. The Expert Consultation agreed that there was insufficient data to complete the risk assessment. Chronic toxicity associated with brevetoxin ingestion is not known.
- No analytical method currently meets the criteria for a Codex Type II or III method. A liquid chromatography-mass spectrometry method or a functional assay should be validated to meet Type II or III criteria.

# Cyclic Imines group

- There have been no reports of adverse effects (acute or chronic) in humans.
- The Expert Consultation considered there was insufficient information to establish an acute reference dose or a tolerable daily intake for the cyclic imines.
- No analytical method currently meets the criteria for a Codex reference method. An existing liquid chromatography-mass spectrometry multi-toxin method should be validated to meet Type II or III criteria.

# Domoic Acid (DA) group

- There was one well-documented episode of human toxicity involving 107 adults.
- Based on available data, a provisional acute reference dose of 0.1 mg DA/kg bw was established by the Expert Consultation.
- A liquid chromatography-UV detection method is recommended for consideration by Codex as the reference method.

#### Okadaic Acid (OA) group

- In humans, DSP causes acute gastrointestinal effects. The Expert Consultation established a provisional acute reference dose of  $0.33 \mu g$  OA equ/kg bw, based on human toxicity data from several countries. No tolerable daily intake could be established because of insufficient data on chronic effects.
- No method exists that meets Codex criteria for a reference method. The most widely used analytical method is the mouse bioassay. However, it is prone to interferences from other toxins. The Expert Consultation recommends a liquid chromatographymass spectrometry method be validated to fully meet Codex Type II or III criteria.

#### Pectenotoxins (PTX) group

- There is no evidence of adverse acute or chronic health effects of pectenotoxins in humans. The Expert Consultation considered that the toxicity database was insufficient to establish an acute reference dose or a tolerable daily intake for these toxins.
- No analytical method exists that meets Codex criteria for a reference method. The Expert Consultation recommends that a liquid chromatography-mass spectrometry method be validated to fully meet Codex Type II or III criteria.

#### Saxitoxin (STX) group

- Human poisonings (including deaths) due to STX have been recorded for many years in many areas of the world. Based on the available data, the Expert Consultation established a provisional acute reference dose of 0.7 µg STX equivalents/kg bw. Because of insufficient data on the chronic effects of STX, no tolerable daily intake could be established.
- The AOAC mouse bioassay is widely used and has provided health protection in many member states for 60 years or more. The Expert Consultation noted several problems with the method that question its validity and use. A liquid chromatography-fluorescence method that has undergone an interlaboratory validation study appears to meet Codex criteria. It is recommended that this method be considered by Codex as a possible reference method.

#### Yessotoxin (YTX) group

- There have been no reports of ill effects in humans attributable to YTX. Based on animal data, the Expert Consultation established a provisional acute reference dose of 50 µg/kg bw. Because of insufficient data on the chronic effects of YTX, no tolerable daily intake could be established.
- No analytical method exists that meets Codex criteria for a reference method. The Expert Consultation recommends that a liquid chromatography-mass spectrometry method be validated to fully meet Codex Type II or III criteria.

# **Monitoring of Growing Areas**

- The Expert Consultation agreed that decisions made on the safety of shellfish can only be based on the direct measurement of toxins in shellfish flesh. However, an integrated shellfish and micro-algal monitoring programme is highly recommended to provide expanded management capability and enhanced consumer protection. For early warning purposes it is recommended to have a programme to monitor growing areas for species of toxin-producing micro-algae. The programme should also include the evaluation of environmental conditions that may indicate the onset of harmful events.
- Because of insufficient data, the occurrence and the concentrations of toxins in bivalve molluscs that may lead to closure of harvesting areas were not fully evaluated during the consultation.
- A micro-algal and shellfish sampling protocol over time and space should include the adequate location and number of sampling sites. Sample size and sampling frequency must be adequate to address spatial-temporal changes in micro-algae and toxins in shellfish.

# **Geographic Distribution of Phytoplankton**

• Micro-algae responsible for the production of the toxins in the saxitoxin, domoic acid and okadaic acid groups, have a world wide distribution. Micro-algae responsible for the production of the remaining toxins have a more restricted geographical distribution. It is suggested that the distribution of all micro-algal species responsible for producing toxins be regarded as potentially worldwide.

# Management of "new toxins" and "new" analogues

- In the case of human intoxication with an unknown "new" toxin, the Expert Consultation recommends that every effort should be made to identify the symptoms and clinical changes in affected individuals, in order to give information on the target site of the new toxin. Samples of the material associated with the intoxication should be gathered and stored for toxicology testing.
- For toxins for which adequate structure-activity data are available, a regulatory decision can be made on the basis of structure. If no adequate information is available, it is proposed that new analogues present in shellfish at less than 5% of the parent toxin should not be regulated against. Compounds present at a concentration greater than 5% of the parent compound should be isolated, characterized and then toxicological properties investigated in order to establish an acute reference dose or tolerable daily intake.

# **Recommendations:**

# To Member States, FAO, WHO:

• Encourage Member states to implement public health programs that ensure that shellfish poisonings are captured in a more systematic way.

- Encourage Member states to generate more toxicological data to perform more accurate risk assessments.
- Promote an increased international effort for the production of certified reference materials and calibration standards.
- Encourage Member states to improve and validate toxin detection methods in shellfish.
- Promote toxicological studies conducted according to OECD guidelines.
- Encourage studies to clarify the mechanism of action for a number of toxin groups.
- Encourage Member states to implement an integrated shellfish and micro-algae monitoring program.
- Consider the position of developing countries regarding implementation of chemical analytical methods.
- Encourage Member states to determine the relationship between quantitative occurrence of toxin producing micro-algae (planktonic and epiphytic) and the accumulation of biotoxins in bivalve molluscs.
- Encourage Member states to develop operational models for forecasting blooms of toxin producing micro-algae in time and space.

#### To Codex:

- Codex should continue to work on risk management recommendations (e.g. Standards and Code of Practice) to address issues related to biotoxins in bivalve molluscs.
- Consideration should be given to the situation in developing countries, when selecting detection methods.

#### To FAO, WHO:

• Establish a standing expert panel to periodically review scientific data and information at the international level.

Toxin Group	LOAEL(1) <sup>a</sup> NOAEL(2) (µg/kg bw)	Safety Factor (human data (H), animal data (A))	Provisional Acute Reference Dose <sup>b</sup>	<b>Derived Guidance Level/ Max</b> <b>Level</b> (based on consumption of 100g (1), 250g (2) and 380g (3))	Guidance Level/Max Level (currently implemented in some countries)
AZA	0.4 (1)	10(H)	0.04 µg/kg	0.024 mg/kg Shellfish Meat (1)	0.16 mg/kg
			2.4 µg/adult	0.0096mg/kg SM (2)	
				0.0063 mg/kg SM (3)	
Brevetoxin			N/A		0.8 mg/kg as PbTx-2
Cyclic Imines			N/A		
DA	1,000 (1)	10(H)	100 µg /kg	60 mg/kg SM(1)	20 mg/kg
			6mg/adult	24 mg/kg SM(2)	
				16 mg/kg SM(3)	
OA	1 (1)	3(H)	0.33µg/kg	0.2 mg/kg SM (1)	0.16 mg/kg
			20 µg/adult	0.08 mg/kg SM (2)	
				0.05 mg/kg SM(3)	
PTX			N/A		
STX	2 (1)	3(H)	0.7 µg/kg	0.42 mg/kg SM(1)	0.8 mg/kg
			42 µg/adult	0.17 mg/kg SM(2)	
				0.11 mg/kg SM(3)	
YTX	5,000 (2)	100(A)	50 μg/kg	30 mg/kg SM(1)	1 mg/kg
			3 mg/adult	12 mg/kg SM(2)	
				8 mg/kg SM(3)	

Table 1: Summary data used in the derivation of acute reference doses, as well as derived and current guidance levels.

<sup>a.</sup> LOAEL= lowest observable adverse effect level; NOAEL= no observable adverse effect level.

<sup>b</sup> based on an adult bw of 60 kg<del>.</del>

## PARTICIPANTS

#### EXPERTS

Dr Per Andersen, Bio/Consult, Denmark Prof Tore Aune, Norwegian School of Veterinary Science, Norway Dr Daniel G. Baden, University of North Carolina Wilmington, United States of America Mrs Catherine Belin<sup>\*</sup> Ifremer Centre de Nantes, France Prof Luis Botana, Univ. Santiago de Compostela, Spain Mr Phil Busby, New Zealand Food Safety Authority, New Zealand Dr Bob Dickey, US Food and Drug Administration, United States of America Dr Valerie Fessard, French Food Safety Agency (AFSSA), France Prof Lora E. Fleming, University of Miami, United States of America Mr John Foorde, Marine and Coastal Management, South Africa Dr Jean-Marc Fremy, French Food Safety Agency (AFSSA), France Dr Sherwood Hall, US Food and Drug Administration, United States of America Dr Philipp Hess. Marine Institute, Ireland Dr Patrick Holland, Cawthron Institute, New Zealand Dr Emiko Ito, Chiba University, Japan Dr Tine Kuiper-Goodman, Health Canada, Canada Dr Jim Lawrence, Health Canada, Canada Mr David Lyons, Food Safety Authority of Ireland, Ireland Dr Rex Munday, AgResearch, New Zealand Prof Yasukatsu Oshima, Tohoku University, Japan Dr Olga Pulido, Health Canada, Canada Dr Michael Quilliam, National Research Council, Canada Prof Gian Paolo Rossini, Universita di Modena e Reggio Emilia, Italy Prof Michael Ryan, University College Dublin, Ireland Dr Covadonga Salgado, Centro do Control do Medio Marino, Spain Dr Joe Silke, Marine Institute, Ireland Dr Gerrit I.A. Speijers, National Institute of Public Health and the Environment, the Netherlands Dr Benjamin Suarez-Isla, Universidad de Chile, Chile Dr Toshivuki Suzuki, Tohoku National Fisheries Research Institute, Japan Dr Andy Tasker, University of Prince Edward Island, Canada Dr Hans P.van Egmond, National Institute of Public Health and the Environment, The Netherlands Dr Phillippe J.P. Verger, Institut National Agronomique Paris-Grignon, France Prof Takeshi Yasumoto, Japan Food Research Laboratories, Japan

#### **RESOURCE PERSONS**

James Hungerford, Chair, AOAC Marine and Freshwater Toxins Task Force, USFDA, USA Ross Jeffree, Head, Marine Environment Laboratory, International Atomic Energy Agency, Monaco Bjørn Røthe Knudtsen, Regional Director, National Food Control Authority, Norway Dr Selma Doyran, Food Standards Officer, Joint FAO/WHO Food Standards Programme, FAO, Italy

#### JOINT FAO/WHO/IOC SECRETARIAT

Hajime Toyofuku, Department of Food Safety - World Health Organization, Switzerland
Lahsen Ababouch, Chief, Fish Utilization and Marketing Service, Fishery Industry Division, Food and Agriculture Organization of the United Nations, Rome, Italy
Henri Loréal, Fishery Industry Officer, Fish Utilization and Marketing Service, FAO, Italy.
Henrik Oksfeldt Enevoldsen, IOC Project Coordinator, IOC of UNESCO, Denmark